Asabys announces today the first investment of its new fund, SAHII II (Sabadell Asabys Healthcare Innovation Investments II), launched with the support of Banco Sabadell, in DeepUll, a Barcelona-based disruptive medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections.
DeepUll raised €13 million Series B financing round in October 2022 from investors like Werfen, Innvierte (CDTI), Kurma Partners, Alta Life sciences, UI Investissement (advised by Mérieux Equity Partners) and Axis Participaciones Empresariales. The investment is devoted to the development of its first-in-class sepsis recognition platform, with the aim to drastically improve patient outcomes and reduce the unnecessary use of antimicrobials. SAHII II’s investment provides additional funding to the company allowing them to continue the development of the technology and its path towards the market.
Josep Ll. Sanfeliu, founding and managing partner at Asabys joining the Board of DeepUll, comments: “DeepUll is the perfect example of a disruptive company in the diagnostic space, led by an outstanding team and using high advanced technologies to solve a clear unmet medical hospital need in the area of infectious diseases.” Ramon Benet, Venture Partner at Asabys, has been instrumental in the analysis of the opportunity. Ramon has a long-time expertise in the In Vitro Diagnostics and Medical Device industries in Europe and in the US, with previous executive roles at Werfen and Instrumentation Laboratory in the US.
Jordi Carrera, Chief Executive Officer and Co-Founder of DeepUll added: “We are delighted to bring Asabys as a new investor to DeepUll. Asabys’ belief in health technologies and their expertise investing in life sciences innovation, add great value to the company, supporting our growth and helping us reach relevant milestones for the ultimate benefit of patients.”
About DeepUll
DeepUll is a medical diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx (sold to QIAGEN in 2018), DeepUll has assembled a team of world-class experts to create rapid, affordable, and accessible diagnostic solutions.
DeepUll’s sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. The product will be a desktop system with end-to-end automation with the aim to be placed in any clinical setting (laboratory, ER, ICU).
About Asabys Partners
Asabys Partners is a venture capital firm specialized in the healthcare sector, founded by Josep Ll. Sanfeliu and Clara Campàs and participated by Alantra. With close to €217 million in AUM and 13 portfolio companies (+1 exit), Asabys invests in highly innovative and disruptive companies covering unmet medical needs in the biopharma and healthtech verticals. Asabys is currently investing from its second fund, Sabadell Asabys Health Innovation Investments (SAHII II), who has Banco Sabadell as anchor investor. https://asabys.com/
Photo (from left to right): Rafel Bru (cofounder DeepUll), Josep Ll. Sanfeliu (Managing Partner Asabys), Jordi Carrera (cofounder DeepUll)
cloud technology axon
ONEtoONE Asset Management ha realizado su quinta inversión fuera de n...
